Know What's Happening in Life

Reviewing the Inability of Anti-Amyloid Immunotherapies to Affect Alzheimer's Disease

A recent Cochrane meta‑analysis of ten anti‑amyloid monoclonal antibodies—including aducanumab, lecanemab and donanemab—shows only trivial cognitive gains and modest functional improvement in patients with mild Alzheimer’s disease, despite clear plaque clearance. The studies also reveal an elevated risk of amyloid‑related imaging abnormalities and inconsistent outcome reporting. These results suggest that amyloid removal alone does not produce meaningful clinical benefits, challenging the long‑standing amyloid cascade hypothesis. Researchers are urged to explore alternative mechanisms such as neuroinflammation or cerebrospinal fluid drainage for disease‑modifying therapies.